Other
Sturge-Weber Syndrome
6
Pipeline Programs↗
0
Active Trials↗
4
Companies Involved↗
Sturge-Weber syndrome is an early-stage landscape with 6 programs across 4 companies. The most active players are Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Jazz Pharmaceuticals, Novartis.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 12
Phase 24
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
7
clinical trials
Completed5 · 71%
Terminated1 · 14%
Withdrawn1 · 14%
Clinical Trials
Trial Activity
7 trials
Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome
Completed·—·Phase 2·NCT02080624·23 enrolled
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome
Completed·—·Phase 1/2·NCT02332655·5 enrolled
Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome
Completed·—·Phase 2/3·NCT03047980·10 enrolled
Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol
Terminated·—·Phase 1·NCT01533376·3 enrolled
Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
Withdrawn·—·Phase 2·NCT01997255
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)